1. Introduction
Tricuspid regurgitation (TR) is often overlooked as a secondary pathological consequence of left-sided heart or pulmonary vascular disease despite its prevalence ranking second only to mitral regurgitation and exceeding that of aortic valve disease. Recent research has drawn increased attention to TR, revealing its association with high mortality rates and unfavorable prognostic outcomes [1,2,3,4].
TR encompasses both primary and secondary forms. Primary TR arises from tricuspid valve (TV) abnormalities. Secondary tricuspid regurgitation (functional TR, FTR), which accounts for approximately 90% of cases, primarily stems from annular dilatation and leaflet embolism due to remodeling of the right ventricle or right atrium caused by left-sided heart disease, atrial fibrillation (AF), or pulmonary disease [1,5,6]. Moreover, it is estimated that a considerable proportion of patients, ranging from 5% to 10%, exhibit severe FTR, a condition commonly linked to device leads and AF [5,7]. Furthermore, patients with persistent AF exhibit greater susceptibility to TR than those with paroxysmal AF [8,9,10], and AF-associated FTR may involve right atrial and tricuspid annular enlargement [11,12].
The 2021 ESC/EACTS guidelines for the management of valvular heart disease classify TV surgery as a class I recommendation for patients with severe isolated primary TR who are symptomatic or have right ventricular dysfunction [13]. However, the perioperative mortality rate associated with isolated TV surgery is considerably high, and no notable disparity is found in survival rates when compared with pharmacological therapy [14,15,16]. Transcatheter annular repair is a viable alternative for repairing the tricuspid annulus owing to its notable benefits, including reduced trauma and expedited recovery [17]. However, the efficacy of transcatheter annular repair in managing severe FTR in patients with AF remains unclear.
K-Clip™ (Huihe Company, Shanghai, China) is an innovative device for transcatheter tricuspid annuloplasty, utilizing a clip-based annular plication technique administered through transjugular venous access, emulating Kay’s annuloplasty. This device efficiently reduces the dimensions of the tricuspid annulus without the need to traverse the valve or puncture the leaflets, thereby mitigating potential damage to the valve [18]. The safety and efficacy of K-Clip™ have been validated in animals by Pan et al. and in humans by Zhang et al. [19,20]. However, there are no research findings on the short-term outcomes of K-Clip™ for patients with severe FTR associated with AF. Consequently, we utilized the K-Clip™ device for the treatment of patients with severe FTR and persistent AF and aimed to assess its short-term feasibility and effectiveness.
2. Material and Methods
2.1. Study Design and Population
This was a retrospective study that included 52 patients with symptomatic severe FTR and persistent AF who were treated with the K-Clip™ annuloplasty system between March 2021 and October 2022. This study was derived from Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip™ Transcatheter Annuloplasty System ([TriStar]; NCT05173233) study, whcih was conducted at nine centers in China. They were Zhongshan Hospital, Fudan University, Shanghai, China, The First Affiliated Hospital, Zhejiang University, Hangzhou, China, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China, Beijing Anzhen Hospital, Capital Medical University, Beijing, Anhui Provincial Hospital, Hefei, China, Fuwai Hospital, China Academy of Medical Sciences, Guangdong province People
2.2. Echocardiographic and Multi-Detector Computed Tomography (CT) Assessment
FTR was assigned a grade of 1 (mild), 2 (moderate), 3 (severe), 4 (massive), and 5 (torrential), as assessed using standard two-dimensional echocardiography [20,21]. Pre-procedural transthoracic echocardiography, transesophageal echocardiography (TEE), and cardiac CT were conducted separately to evaluate the anatomical suitability for implantation of the K-Clip™ device. All echocardiographic images were analyzed in an independent laboratory.
The target point for anchoring was set by the mid-posterior annulus and moved forward to the anteroposterior commissure when the TR jet derived from the anterolateral annulus was dominant. A cardiac CT scan was utilized for sizing the tricuspid annulus to aid in the selection of implant length and planning of the procedure, thereby reducing the risk of injury to the right coronary artery (RCA) and facilitating the generation of the intended views. The device size was primarily determined by the length of the tricuspid annulus, as measured using cardiac CT, during the maximal diastolic opening of the tricuspid valve.
2.3. Investigational Device
Tricuspid transcatheter edge-to-edge valve repair was performed using the K-Clip™ transcatheter tricuspid annuloplasty device, which was the “clamp-annular-screw sandwich structure” formed by two clamp arms and one anchor screw. It is administered via transjugular venous access using an external guide (18F) and a maneuverable inner delivery catheter (15F). The current K-Clip™ device can be used with four different clip arm lengths (12, 14, 16, 18 mm), corresponding to a maximum reduction in annual lengths ranging from 24 mm to 36 mm.
2.4. Procedural Technique
The femoral vein was used as the access point for surgery, with patients undergoing general anesthesia guided by fluoroscopy and TEE. TEE has been used for guidance during the procedure of TR intervention therapies [22,23]. The catheter was guided to the target site in the tricuspid annulus following right coronary angiography, and the anchor located within the clip arm was subsequently inserted into the annulus, at a regulated depth of 4 mm, with echocardiographic guidance from the X-plane. The procedure of transcatheter annular repair with K-Clip™ under TEE was as previously reported and is shown in Figure 1 [24]. Under TEE, the clip arms were opened and positioned tangentially to the tricuspid annulus. The adjacent annulus tissue was drawn into the clip by retracting the anchor. The tooth clip arms were then closed to accomplish sandwiching of the annulus. After RCA coronary angiography and echocardiographic confirmation of TR reduction, the final detachment was performed. Heparin was administered intravenously to attain an active clotting time ranging from 300 to 600 s. After discharge, it was advised that oral anticoagulant therapy be initiated for patients.
2.5. Study Endpoints and Follow-Up
Clinical success was defined as procedural success without any major adverse events (MAEs) within a 30-day period. In the present study, MAEs encompassed a range of outcomes including all-cause mortality, cardiovascular mortality, rehospitalization, conversion to surgery, additional minimally invasive interventions, puncture site injury, bleeding events, major vascular complications, worsening of renal insufficiency, stroke, left-sided heart failure, anemia, pericardial effusion, hyperkalemia, myocardial infarction, and a new bundle branch block. The New York Heart Association (NYHA) functional class, 6-min-walk distance (6 MWD), and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores were used as the principal metrics for assessing prognosis (life quality outcome).
Furthermore, the FTR grade and various echocardiographic parameters, such as anatomic and hemodynamic alterations of the right ventricle and tricuspid valve, were acquired at the 30-day follow-up and assessed in an echo core laboratory.
2.6. Statistical Analysis
Continuous variables were presented as mean ± standard deviation, and categorical variables were expressed as proportions (%). To compare the baseline and post-procedure follow-up measurements, continuous variables were analyzed using the paired Student’s t-test, whereas categorical variables were compared using the Wilcoxon signed-rank test. A two-sided p-value of <0.05 was deemed statistically significant. All data analyses were performed using STATA software 15.1 (Stata Corp LP, College Station, TX, USA).
3. Results
3.1. General Characteristics of Patients
The baseline characteristics of all enrolled patients are shown in Table 1. A total of 96 patents underwent transcatheter tricuspid annuloplasty with K-ClipTM, and 15 subjects and 29 subjects were excluded because of the absence of AF and paroxysmal AF, respectively. As shown in Figure 2, 52 patients (23 men and 29 women) were enrolled in this study, with a mean age of 74.02 ± 7.03 years. Comorbidities included hyperlipidemia (n = 7, 13.4%), hypertension (n = 26, 73.33%), diabetes mellitus (n = 8, 15.3%), peripheral vascular disease (n = 4, 7.6%), renal insufficiency (n = 3, 5.7%), NYHA functional class III or IV (n = 31, 59.6%), myocardial infarction (n = 2, 3.8%), and stroke (n = 13, 25%). Furthermore, 1 patient (1.9%) had previously undergone percutaneous coronary intervention. The medications used at the baseline are presented in Table 2. All patients were prescribed nitrates and diuretics, with additional percentages of 19.2%, 40.3%, and 19.2% of patients also prescribed digoxin, beta-blockers, and calcium channel blockers, respectively.
3.2. Procedural Results
During the surgical procedure, essential information regarding the patient surgeries was recorded. As shown in Table 3, 24 patients were implanted with more than two clips (46.1%), and the delivery system was retrieved as intended. All patients achieved procedural success (100%) with a mean operation time and radian exposure of 2.64 ± 1.09 h and 133.33 ± 743.06 mGy, respectively. (Table 3)
3.3. In-Hospital and 30-Day Complications
The mean duration of hospitalization was 5.16 ± 3.56 days. The in-hospital and 30-day complications are summarized in Table 4. A low MAE occurrence rate was observed in the study population before discharge. One patient reported major vascular bleeding at the transjugular access site; however, no invasive intervention was required. During the 30-day follow-up, one new incidence of stroke (1.9%), one of left-sided heart failure (1.9%), two of anemia (3.8%), three of pericardial effusion (5.7%).
3.4. Improvement in Cardiac Function Between the Baseline and 30-Day Follow-Up
Cardiac ultrasound suggested a significant decrease in TR as the percentage of patients with moderate to severe regurgitation reduced to 26.9%, and severe regurgitation persisted in only two patients (3.8%). As shown in Figure 3 and Table 5, the regurgitation volume decreased from an average of 73.21 ± 53.92 to 29.35 ± 20.78, (p < 0.001), combined with a marked reduction in effective regurgitation orifice area (0.99±1.18 vs. 0.34 ± 0.25, p < 0.001) and tricuspid annulus diameter (42.48 ± 5.34 vs. 36.17 ± 4.45, p < 0.001). Right heart remodeling was reversed, which presented in the right-heart parameters postoperatively with a reduction in right ventricular end-diastolic diameter (left to right, 60.02 ± 11.25 vs. 54.05 ± 11.98, p = 0.011; top to bottom, 73.53 ± 13.94 vs. 64.88 ± 14.68, p = 0.003) and right ventricular end-diastolic diameter (base, 46.62 ± 7.14 vs. 41.43 ± 6.83, p < 0.001). Furthermore, the inferior vena cava width also decreased from 22.93 ± 5.25 to 18.64 ± 6.39 (p < 0.001). The PASP reduced from 42.60 ± 7.33 to 35.96 ± 6.90 (p < 0.001), whereas CO increased from 4.59 ± 1.65 to 5.53 ± 2.13 (p = 0.013).
For cardiac function assessment, significant improvement in NYHA functional class was observed at the 30-day follow-up (p < 0.001) (Figure 4). The prevalence of NYHA functional class ≥ III was significantly reduced (p < 0.001). Additionally, the quality of life, according to the KCCQ score, improved significantly (p < 0.001) (Figure 4). Despite the lack of significant difference, a favorable trend towards improved exercise capacity based on the 6MWD at 30 days was also observed (Figure 5).
4. Discussion
To the best of our knowledge, this is the first study to investigate the short-term outcomes of the K-Clip™ transcatheter annular repair system for patients with severe FTR associated with persistent AF and without structural heart disease. The present study showed low rates of complications and sustained improvement in functional status at the 30-day follow-up, providing evidence of the safety and efficacy of K-Clip™ for severe FTR associated with persistent AF.
Patients with severe FTR and AF are prone to have annular dilatation. In the present study, the TV annular area was significantly larger than normal. The development of FTR can be attributed to several diseases, including AF, left-sided heart disease, and increased right ventricular afterload, with or without pulmonary hypertension. For FTR associated with AF, the annular dilatation is caused by RA dilatation, which, in turn, accelerates the dilatation of the tricuspid annulus. This promotes the persistence of AF; thus TR begets TR, forming a vicious cycle. Utsunomiya et al. used three-dimensional echocardiography to assess FTR and demonstrated that, in patients with chronic AF, the TV annulus area, RA dilatation, and tricuspid leaflet tethering area were larger and smaller, respectively, than those in patients with left-sided heart disease [12].
We demonstrated the short-term safety and efficacy of transcatheter in patients with severe FTR and persistent AF. Current guidelines recommend TV surgery for patients with at least moderate TR who are undergoing left-sided valve surgery (level of evidence I) and for symptomatic patients with severe isolated primary and secondary TR (level of evidence IIa and IIb, respectively) [7]. Furthermore, many studies have reported transcatheter TR treatment in patients after left-sided valve surgery or dysfunction [25]. However, no study has investigated the results of transcatheter treatment in patients with severe AF-related FTR. Because atrial and ventricular dilations both cause TV annulus dilation, a similar treatment indication may also be applied to AF-related FTR. Furthermore, based on Kay’s annuloplasty, the principle of the K-Clip™ system was to reduce the size of the annulus by a figure 8 suture plication of the posterior leaflet, shortening the distance between anterior and posterior-septal leaflets, and resulting in a functional bicuspid valve.
Our results demonstrated that the K-Clip™ annuloplasty system achieved 100% procedural success in all 52 cases, and a low in-hospital or 30-day MAE occurrence rate was reported thereafter. Several types of tricuspid annuloplasty are available, including suture-based (TriAlign (Mitralign Inc., Bost on, MA, USA) and TriCinch (4Tech Cardio, Galway, Ireland) devices), minimally invasive tricuspid annuloplasty with pledget-assisted sutures, and ring-based annuloplasty. The Cardioband device (Edwards Lifesciences, Irvine, CA, USA) has been widely studied and used in clinical practice. Davidson et al. recently reported that the Cardioband device achieved a success rate of 93% without death in the first 30 days and significantly reduced the septolateral tricuspid annular diameter and TR grade. Furthermore, modifications to the reduced anchors, together with the clip-clasping approach, were embedded in the refined design. Based on that, the K-Clip™ system theoretically avoids repeated annulus penetration and offers a flexible and repositionable implantation order to attain TR reduction.
A significant reduction in FTR was observed after treatment with K-Clip™ in patients with severe FTR and persistent AF, with few complications. The size of the right atrium was markedly decreased. However, it remains unclear whether patients should undergo radiofrequency ablation. In patients with AF and TR, AF may lead to atrial remodeling despite undergoing tricuspid annuloplasty because persistent AF has not yet been controlled. Therefore, research with a prolonged follow-up period is needed to investigate long-term prognosis.
5. Limitations
This study has certain limitations. First, our sample size was small; more patients should be included in further studies. Second, the duration of the follow-up was short, and our results need to be confirmed over extended periods. Third, no comparison was made between groups of patients without AF and those with paroxysmal AF. Indeed, we are considering a randomized controlled trial that includes such groups. The above conclusions need to be confirmed with the support of more adequate data.
6. Conclusions
Tricuspid annuloplasty with K-Clip™ in patients with severe FTR and persistent AF resulted in a favorable short-term prognosis and significant improvement in TR. Therefore, K-Clip™ could be a novel option for those suffering from severe FTR accompanied with AF.
Conceptualization, D.-X.Z. and X.-C.Z.; methodology, J.-X.M.; software, Y.-M.Q.; formal analysis, L.-W.Z.; investigation, D.-W.L.; manuscript writing and data curation, D.-W.L., J.-N.F. and Z.Z.; visualization, M.-F.M.; supervision, W.-Z.P., X.-C.Z. and J.-B.G. All authors have read and agreed to the published version of the manuscript.
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by institutional review board at Zhongshan Hospital, Fudan University, Shanghai, China. In addition, the protocol was approved by institutional review board at each participating site. All individuals in the study provided written informed consent, and the research was approved by the Institutional Review Board of Zhongshan Hospital, Fudan University, Shanghai, China (Number 2022-042).
The authors confirm that patient consent forms have been obtained for this article.
The data that support the findings of this study are available from the corresponding author upon reasonable request.
The authors declare no conflicts of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 1. Procedural imaging. (A) The K-clip system was introduced percutaneously via the right jugular vein; (B) the anchor within the clip was affixed to the mid-posterior annulus; (C) the annular tissue was drawn into the clip, and subsequently, the clip closed; and (D) the clip was released.
Figure 4. Paired improvements in NYHA functional class and TR severity in 30 days (all p [less than] 0.001).
Figure 5. Improvements in KCCQ scores and 6WMD in 30 days (all p [less than] 0.001).
Baseline characteristics of patients with atrial fibrillation treated with K-clip.
Patient Characteristics | N = 52 |
---|---|
Age, yrs | 74.02 ± 7.03 |
Male (n, %) | 23/52 (44.2%) |
Hyperlipidemia (n, %) | 7/52 (13.4%) |
Hypertension (n, %) | 26/52 (50.0%) |
Diabetes mellitus (n, %) | 8/52 (15.3%) |
Peripheral vascular disease (n, %) | 4/52 (7.6%) |
Renal insufficiency (n, %) | 3/52 (5.7) |
Left bundle branch block (n, %) | 0/52 (0%) |
Right bundle branch block (n, %) | 0/52 (0.0%) |
Atrioventricular block (n, %) | 0/52 (0.0%) |
NYHA functional class III or IV (n, %) | 32/52 (61.5%) |
Myocardial infarction (n, %) | 2/52 (3.8%) |
Stroke (n, %) | 13/52 (25%) |
Previous PCI (n, %) | 1/52 (1.9%) |
Previous CABG (n, %) | 0/52 (0.0%) |
Abbreviations: NYHA, New York Cardiac Function; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.
Drug history of patients with atrial fibrillation treated with K-clip.
Drug History | N = 52 |
---|---|
digoxin (n, %) | 10/52 (19.2%) |
Betaloc (n, %) | 21/52 (40.3%) |
calcium channel blockers (n, %) | 10/52 (19.2%) |
nitrates (n, %) | 52/52 (100%) |
diuretics (n, %) | 52/52 (100%) |
Surgery information of patients with atrial fibrillation treated with K-clip.
Surgery Information | N = 52 |
---|---|
implantation of clips ≥ 2 (n, %) | 24/52 (46.1%) |
total duration of surgery (hour) | 2.64 ± 1.09 |
radiant exposure/mGy | 1100 (1456.5, 850) |
duration of hospitalization (day) | 5.16 ± 3.56 |
Clinical end points of patients with atrial fibrillation treated with K-clip.
Clinical End Points | In-Hospital | 30-Days |
---|---|---|
N = 52 | N = 52 | |
Primary endpoints | ||
All-cause mortality (n, %) | 0 (0.0%) | 0 (0.0%) |
Cardiovascular mortality (n, %) | 0 (0.0%) | 0 (0.0%) |
Secondary endpoints | ||
Re-hospitalization (n, %) | - | 0 (0.0%) |
Converted to surgery (n, %) | 0 (0.0%) | 0 (0.0%) |
Additional minimally invasive interventions during (n, %) | 0 (0.0%) | 0 (0.0%) |
Puncture site injury (n, %) | 0 (0.0%) | 0 (0.0%) |
Bleeding event (n, %) | 0 (0.0%) | 1 (1.9%) |
Major | 1 (1.9%) | 0 (0.0%) |
Worsening of renal insufficiency (n, %) | 0 (0.0%) | 0 (0.0%) |
Stroke (n, %) | 0 (0.0%) | 0 (0.0%) |
Left heart failure (n, %) | 0 (0.0%) | 1 (1.9%) |
Anemic (n, %) | 0 (0.0%) | 2 (3.8%) |
Pericardial effusion (n, %) | 0 (0.0%) | 3 (5.7%) |
Hyperkalemia (n, %) | 0 (0.0%) | 0 (0.0%) |
Hypokalemia (n, %) | 0 (0.0%) | 0 (0.0%) |
Myocardial infarction (n, %) | 0 (0.0%) | 0 (0.0%) |
New brunch block (n, %) | 0 (0.0%) | 0 (0.0%) |
New atrioventricular block | 0 (0.0%) | 0 (0.0%) |
Comparison between baseline and 30-day imaging information of patients with atrial fibrillation treated with K-clip.
Baseline | 30 Days | p-Value | |
---|---|---|---|
Echocardiography | |||
RAED (left to right) (mm) | 60.02 ± 11.25 | 54.05 ± 11.98 | 0.011 |
RAED (top to bottom) (mm) | 73.53 ± 13.94 | 64.88 ± 14.68 | 0.003 |
RVED (middle) (mm) | 34.00 ± 6.70 | 31.04 ± 6.12 | 0.020 |
RVED (base) (mm) | 46.62 ± 7.14 | 41.43 ± 6.83 | <0.001 |
Tricuspid annulus diameter (anterior to posterior) (mm) | 42.48 ± 5.34 | 36.17 ± 4.45 | <0.001 |
Diameter (septal side) (mm) | 42.77 ± 5.47 | 37.63 ± 5.55 | <0.001 |
Reduced flow path width (mm) | 12.40 ± 4.66 | 6.22 ± 3.66 | <0.001 |
Moderate to severe regurgitation (VC) | 52/52 (100%) | 14/52(26.9%) | <0.001 |
Effective regurgitation orifice area (cm2) | 0.99 ± 1.18 | 0.34 ± 0.25 | <0.001 |
Moderate to severe regurgitation (PISA) | 52/52 (100%) | 17/52 (32.7%) | <0.001 |
Moderate to severe regurgitation (combined PISA and VC) | 52/52 (100%) | 16/52 (30.8%) | <0.001 |
Regurgitation Volume (cm3) | 73.21 ± 53.92 | 29.35 ± 20.78 | <0.001 |
Mean transvalve pressure (mmHg) | 1.10 ± 0.45 | 1.15 ± 0.50 | 0.539 |
TAPSE (mm) | 18.05 ± 3.09 | 18.08 ± 5.31 | 0.973 |
FAC (%) | 39.48 ± 7.02 | 39.68 ± 10.66 | 0.909 |
Inferior vena cava width (mm) | 22.93 ± 5.25 | 18.64 ± 6.39 | <0.001 |
PASP (mmHg) | 42.60 ± 7.33 | 35.96 ± 6.90 | <0.001 |
LVEF (%) | 60.77 ± 7.33 | 61.46 ± 6.58 | 0.615 |
LVEDd (cm3) | 103.29 ± 30.88 | 108.48 ± 33.22 | 0.412 |
LVEDs (cm3) | 40.53 ± 14.88 | 38.67 ± 15.06 | 0.528 |
CO (mL/min) | 4.59 ± 1.65 | 5.53 ± 2.13 | 0.013 |
Abbreviations: RAED: right atrial end-diastolic diameter; RVED: right ventricular end-diastolic diameter; FAC: fractional area change; PASP: pulmonary artery systolic pressure; LVEF: left ventricular ejection fraction; LVEDd: left ventricular end-diastolic dimension; LVEDs: left ventricular end-systolic dimension; CO: cardiac output.
References
1. Chorin, E.; Rozenbaum, Z.; Topilsky, Y.; Konigstein, M.; Ziv-Baran, T.; Richert, E.; Keren, G.; Banai, S. Tricuspid regurgitation and long-term clinical outcomes. Eur. Heart J. Cardiovasc. Imaging; 2020; 21, pp. 157-165. [DOI: https://dx.doi.org/10.1093/ehjci/jez216] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31544933]
2. Messika-Zeitoun, D.; Verta, P.; Gregson, J.; Pocock, S.J.; Boero, I.; Feldman, T.E.; Abraham, W.T.; Lindenfeld, J.; Bax, J.; Leon, M. et al. Impact of tricuspid regurgitation on survival in patients with heart failure: A large electronic health record patient-level database analysis. Eur. J. Heart Fail.; 2020; 22, pp. 1803-1813. [DOI: https://dx.doi.org/10.1002/ejhf.1830] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32367642]
3. Wang, N.; Fulcher, J.; Abeysuriya, N.; McGrady, M.; Wilcox, I.; Celermajer, D.; Lal, S. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: A systematic review and meta-analysis. Eur. Heart J.; 2019; 40, pp. 476-484. [DOI: https://dx.doi.org/10.1093/eurheartj/ehy641] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30351406]
4. Rao, V.N.; Giczewska, A.; Chiswell, K.; Felker, G.M.; Wang, A.; Glower, D.D.; Gaca, J.G.; Parikh, K.S.; Vemulapalli, S. Long-term outcomes of phenoclusters in severe tricuspid regurgitation. Eur. Heart J.; 2023; 44, pp. 1910-1923. [DOI: https://dx.doi.org/10.1093/eurheartj/ehad133]
5. Prihadi, E.A.; Delgado, V.; Leon, M.B.; Enriquez-Sarano, M.; Topilsky, Y.; Bax, J.J. Morphologic Types of Tricuspid Regurgitation: Characteristics and Prognostic Implications. JACC Cardiovasc. Imaging; 2019; 12, pp. 491-499. [DOI: https://dx.doi.org/10.1016/j.jcmg.2018.09.027]
6. Wang, P.; Huang, Y.; Sun, L.; Han, Z. Surgical Treatment Strategy of Functional Tricuspid Regurgitation. Rev. Cardiovasc. Med.; 2024; 25, 182. [DOI: https://dx.doi.org/10.31083/j.rcm2505182]
7. Otto, C.M.; Otto, C.M.; Nishimura, R.A.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P., 3rd; Gentile, F.; Jneid, H.; Krieger, E.V.; Mack, M. et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation; 2021; 143, pp. e35-e71.
8. Bonapace, S.; Marinelli, A.; Costa, A.; Trachanas, K.; Molon, G. Atrial Fibrillation, Tricuspid Regurgitation, and Pacemaker: A Vicious Circle. J. Am. Coll. Cardiol.; 2023; 81, e139. [DOI: https://dx.doi.org/10.1016/j.jacc.2022.12.032]
9. Patlolla, S.H.; Schaff, H.V.; Nishimura, R.A.; Stulak, J.M.; Chamberlain, A.M.; Pislaru, S.V.; Nkomo, V.T. Incidence and Burden of Tricuspid Regurgitation in Patients with Atrial Fibrillation. J. Am. Coll. Cardiol.; 2022; 80, pp. 2289-2298. [DOI: https://dx.doi.org/10.1016/j.jacc.2022.09.045]
10. Ruf, T.F.; Gossler, T.A.M.; von Bardeleben, R.S. Understanding Atrial Fibrillation and Atrial Secondary Tricuspid Regurgitation: The Chicken or the Egg?. J. Am. Coll. Cardiol.; 2022; 80, pp. 2299-2300. [DOI: https://dx.doi.org/10.1016/j.jacc.2022.10.009]
11. Najib, M.Q.; Vinales, K.L.; Vittala, S.S.; Challa, S.; Lee, H.R.; Chaliki, H.P. Predictors for the development of severe tricuspid regurgitation with anatomically normal valve in patients with atrial fibrillation. Echocardiography; 2012; 29, pp. 140-146. [DOI: https://dx.doi.org/10.1111/j.1540-8175.2011.01565.x]
12. Utsunomiya, H.; Itabashi, Y.; Mihara, H.; Berdejo, J.; Kobayashi, S.; Siegel, R.J.; Shiota, T. Functional Tricuspid Regurgitation Caused by Chronic Atrial Fibrillation: A Real-Time 3-Dimensional Transesophageal Echocardiography Study. Circ. Cardiovasc. Imaging; 2017; 10, e004897. [DOI: https://dx.doi.org/10.1161/CIRCIMAGING.116.004897] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28073806]
13. Vahanian, A. Corrigendum to: 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J.; 2022; 43, pp. 561-632. [DOI: https://dx.doi.org/10.1093/eurheartj/ehab395] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34453165]
14. Zack, C.J.; Fender, E.A.; Chandrashekar, P.; Reddy, Y.N.; Bennett, C.E.; Stulak, J.M.; Miller, V.M.; Nishimura, R.A. National Trends and Outcomes in Isolated Tricuspid Valve Surgery. J. Am. Coll. Cardiol.; 2017; 70, pp. 2953-2960. [DOI: https://dx.doi.org/10.1016/j.jacc.2017.10.039] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29241483]
15. Alqahtani, F.; Berzingi, C.O.; Aljohani, S.; Hijazi, M.; Al-Hallak, A.; Alkhouli, M. Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation. J. Am. Heart Assoc.; 2017; 6, e007597. [DOI: https://dx.doi.org/10.1161/JAHA.117.007597]
16. Axtell, A.L.; Bhambhani, V.; Moonsamy, P.; Healy, E.W.; Picard, M.H.; Sundt, T.M.; Wasfy, J.H. Surgery Does Not Improve Survival in Patients with Isolated Severe Tricuspid Regurgitation. J. Am. Coll. Cardiol.; 2019; 74, pp. 715-725. [DOI: https://dx.doi.org/10.1016/j.jacc.2019.04.028]
17. Russo, G.; Taramasso, M.; Pedicino, D.; Gennari, M.; Gavazzoni, M.; Pozzoli, A.; Maisano, F. Challenges and future perspectives of transcatheter tricuspid valve interventions: Adopt old strategies or adapt to new opportunities?. Eur. J. Heart Fail.; 2022; 24, pp. 442-454. [DOI: https://dx.doi.org/10.1002/ejhf.2398]
18. Sisinni, A.; Estevez-Loureiro, R. The K-clip™: Time for a new tricuspid valve focal annuloplasty system. Int. J. Cardiol.; 2023; 390, 131234. [DOI: https://dx.doi.org/10.1016/j.ijcard.2023.131234]
19. Zhang, X.; Jin, Q.; Pan, W.; Li, W.; Guo, Y.; Ma, G.; Pan, C.; Chen, S.; Zhang, Y.; Zhang, L. et al. First-in-human study of the K-Clip™ transcatheter annular repair system for severe functional tricuspid regurgitation. Int. J. Cardiol.; 2023; 390, 131174. [DOI: https://dx.doi.org/10.1016/j.ijcard.2023.131174]
20. Pan, W.; Long, Y.; Zhang, X.; Chen, S.; Li, W.; Pan, C.; Guo, Y.; Zhou, D.; Ge, J. Feasibility Study of a Novel Transcatheter Tricuspid Annuloplasty System in a Porcine Model. JACC Basic Transl. Sci.; 2022; 7, pp. 600-607. [DOI: https://dx.doi.org/10.1016/j.jacbts.2022.02.022]
21. Hahn, R.T.; Zamorano, J.L. The need for a new tricuspid regurgitation grading scheme. Eur. Heart J. Cardiovasc. Imaging; 2017; 18, pp. 1342-1343. [DOI: https://dx.doi.org/10.1093/ehjci/jex139] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28977455]
22. Pizzino, F.; Trimarchi, G.; D’agostino, A.; Bonanni, M.; Benedetti, G.; Paradossi, U.; Manzo, R.; Capasso, R.; Di Bella, G.; Zito, C. et al. Impact of Leaflet-to-Annulus Index on Residual Regurgitation Following Transcatheter Edge-to-Edge Repair of the Tricuspid Valve. J. Clin. Med.; 2024; 13, 4176. [DOI: https://dx.doi.org/10.3390/jcm13144176] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/39064216]
23. Tanaka, T.; Sugiura, A.; Kavsur, R.; Vogelhuber, J.; Öztürk, C.; Becher, M.U.; Zimmer, S.; Nickenig, G.; Weber, M. Leaflet-to-annulus index and residual tricuspid regurgitation following tricuspid transcatheter edge-to-edge repair. EuroIntervention; 2022; 18, pp. e169-e178. [DOI: https://dx.doi.org/10.4244/EIJ-D-21-00862] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35193837]
24. Lee, A.P.-W.; Ni, Y.; Lam, Y.-Y. Imaging for Transcatheter Tricuspid Annuloplasty Using the K-Clip Device. Circ. Cardiovasc. Imaging; 2023; 16, e015033. [DOI: https://dx.doi.org/10.1161/CIRCIMAGING.122.015033] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36752091]
25. Davidson, L.J.; Tang, G.H.; Ho, E.C.; Fudim, M.; Frisoli, T.; Camaj, A.; Bowers, M.T.; Masri, S.C.; Atluri, P.; Chikwe, J. et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation; 2024; 149, pp. e1223-e1238. [DOI: https://dx.doi.org/10.1161/CIR.0000000000001232]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background: Atrial fibrillation (AF) has been identified as a risk factor for functional tricuspid regurgitation (FTR) in the absence of other known etiologies, although limited interventional options are available. K-Clip™, a novel transcatheter tricuspid annuloplasty device, is a clip-based annular plication approach for FTR. To date, no studies have investigated the short-term outcomes of K-Clip™ for patients with severe FTR associated with AF. Therefore, the aim of this study was to explore the feasibility and effectiveness of transcatheter annular repair with K-Clip™ for FTR in patients with persistent AF. Methods: Patients with FTR and persistent AF who underwent transcatheter annular repair with K-Clip™ at nine centers in China during the inclusion period were included (This study derived from Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip™ Transcatheter Annuloplasty System [TriStar study}). Baseline data, imaging results, and follow-up data were collected. Results: All 52 patients (23 men, 74.02 ± 7.03 years) received successful intervention, and the mean operation time and radian exposure were 2.64 ± 1.09 h and 133.33 ± 743.06 mGy, respectively. No death cases and a low major adverse event occurrence rate were reported in 30 days. A significant decrease in FTR was documented, and TR remained severe in only two patients (3.8%). The regurgitation volume decreased significantly, accompanied by a notable reduction in the effective regurgitation orifice area and tricuspid annulus diameter, which subsequently led to the reversal of right heart remodeling. Furthermore, a decrease in pulmonary artery systolic pressure and an increase in cardiac output were documented. Conclusions: Transcatheter annular repair with K-Clip™ showed favorable short-term prognosis and significant improvement in FTR in patients with severe FTR associated with persistent AF. K-Clip™ could be a novel option for that group of patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;
2 Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China;
3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;